A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis… (NCT07657572) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.
1,000 participantsStarted 2026-06
Plain-language summary
A multi-center, prospective, registry study to analyze the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients diagnosed with peripheral T-cell lymphoma (PTCL) by histopathology from June 2026 to December 2029 and detected by gene sequencing (NGS) with different molecular subtypes.
* Patients diagnosed with PTCL by histopathology from January 2026 to June 2026 and NGS detection can be performed if there is tumor tissue.
* Fully understand the study, voluntarily sign the written informed consent form (ICF), and agree to cooperate with genetic testing, treatment, efficacy assessment and long-term follow-up.
* Age ≥ 18 years
Exclusion Criteria:
* Female patients who are pregnant, breastfeeding, or of childbearing potential without effective contraception;
* Subjects with poorly controlled neurological, psychiatric, mental or cognitive disorders that may impair their understanding and signing of the informed consent form as well as adherence to the study procedures;
* Any other conditions deemed inappropriate for enrollment by the investigator.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a registry study and not yet recruiting, it's not testing a new treatment — so how would joining this study actually affect my day-to-day care compared to just receiving standard treatment on its own?
2This study is focused on tracking how different molecular subtypes of peripheral T-cell lymphoma behave over time using progression-free survival as the key measure — do you know which molecular subtype my PTCL is, and would that information matter for my treatment decisions right now regardless of this trial?
3Because this is a registry study with no assigned phase, there's no experimental drug being tested — but what kinds of data collection, tests, or follow-up visits would I likely be committing to if I were to participate once it opens?
4Given that this study hasn't started recruiting yet, is there a currently available trial or standard treatment pathway I should be focusing on in the meantime rather than waiting to see if this registry opens near me?
5Since the study spans multiple centers and is designed to analyze prognosis across different PTCL subtypes, would my participation contribute to research that might help future patients with my specific subtype, and is that something you think would be worth discussing further when it becomes available?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Progression-free survival
Timeframe: Baseline up to data cut-off (up to approximately 4 years)